Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Mar;65(3):936–942. doi: 10.1128/iai.65.3.936-942.1997

Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum.

P Zhou 1, M C Sieve 1, R P Tewari 1, R A Seder 1
PMCID: PMC175072  PMID: 9038300

Abstract

Infection with Histoplasma capsulatum results in a subclinical infection in immunocompetent hosts due to an effective cellular immune response. By contrast, immunodeficient individuals can have a severe disseminated and potentially fatal disease. In a previous study, it was demonstrated that normal mice infected intravenously with H. capsulatum and treated with interleukin-12 (IL-12) at the time of infection were protected from a fatal outcome. In this study, we examined the immunomodulatory effects of IL-12 on disseminated histoplasmosis in immunodeficient SCID mice. SCID mice infected with H. capsulatum and treated with IL-12 showed an increase in survival and a reduction in the colony counts of H. capsulatum in internal organs at 14 days after infection. The protective effect of IL-12 was abrogated if animals were also treated with a neutralizing antibody to gamma interferon (IFN-gamma). IL-12 treatment also resulted in an increase in mRNA expression and protein production for IFN-gamma, tumor necrosis factor alpha (TNF-alpha), and nitric oxide from spleen cells. When IL-12 was combined with amphotericin B (AmB) treatment, there was a significant increase in survival compared with either modality alone. Moreover, combined treatment resulted in an increase in both IFN-gamma and TNF-alpha production, as well as in a substantial reduction in H. capsulatum burden at 35 and 90 days postinfection. This study demonstrates that IL-12 modulates the protective immune response to histoplasmosis in SCID mice and also suggests that IL-12 in combination with AmB may be useful as a treatment for H. capsulatum in immunodeficient hosts.

Full Text

The Full Text of this article is available as a PDF (312.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barral-Netto M., Barral A., Brownell C. E., Skeiky Y. A., Ellingsworth L. R., Twardzik D. R., Reed S. G. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science. 1992 Jul 24;257(5069):545–548. doi: 10.1126/science.1636092. [DOI] [PubMed] [Google Scholar]
  2. Bistoni F., Vecchiarelli A., Mazzolla R., Puccetti P., Marconi P., Garaci E. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother. 1985 Apr;27(4):625–631. doi: 10.1128/aac.27.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brummer E., Kurita N., Yoshida S., Nishimura K., Miyaji M. Killing of Histoplasma capsulatum by gamma-interferon-activated human monocyte-derived macrophages: evidence for a superoxide anion-dependent mechanism. J Med Microbiol. 1991 Jul;35(1):29–34. doi: 10.1099/00222615-35-1-29. [DOI] [PubMed] [Google Scholar]
  4. Cherwinski H. M., Schumacher J. H., Brown K. D., Mosmann T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987 Nov 1;166(5):1229–1244. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chia J. K., McManus E. J. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother. 1990 May;34(5):906–908. doi: 10.1128/aac.34.5.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chia J. K., Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis. 1989 Jan;159(1):113–116. doi: 10.1093/infdis/159.1.113. [DOI] [PubMed] [Google Scholar]
  7. Clemons K. V., Brummer E., Stevens D. A. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother. 1994 Mar;38(3):460–464. doi: 10.1128/aac.38.3.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Curry R. C., Kiener P. A., Spitalny G. L. A sensitive immunochemical assay for biologically active MuIFN-gamma. J Immunol Methods. 1987 Nov 23;104(1-2):137–142. doi: 10.1016/0022-1759(87)90497-2. [DOI] [PubMed] [Google Scholar]
  9. D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med. 1995 Feb 1;181(2):537–546. doi: 10.1084/jem.181.2.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Deepe G. S., Jr Role of CD8+ T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J Immunol. 1994 Apr 1;152(7):3491–3500. [PubMed] [Google Scholar]
  11. Deepe G. S., Jr The immune response to Histoplasma capsulatum: unearthing its secrets. J Lab Clin Med. 1994 Feb;123(2):201–205. [PubMed] [Google Scholar]
  12. Fleischmann J., Wu-Hsieh B., Howard D. H. The intracellular fate of Histoplasma capsulatum in human macrophages is unaffected by recombinant human interferon-gamma. J Infect Dis. 1990 Jan;161(1):143–145. doi: 10.1093/infdis/161.1.143. [DOI] [PubMed] [Google Scholar]
  13. Gazzinelli R. T., Hieny S., Wynn T. A., Wolf S., Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6115–6119. doi: 10.1073/pnas.90.13.6115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hsieh C. S., Macatonia S. E., Tripp C. S., Wolf S. F., O'Garra A., Murphy K. M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993 Apr 23;260(5107):547–549. doi: 10.1126/science.8097338. [DOI] [PubMed] [Google Scholar]
  15. Hunter C. A., Bermudez L., Beernink H., Waegell W., Remington J. S. Transforming growth factor-beta inhibits interleukin-12-induced production of interferon-gamma by natural killer cells: a role for transforming growth factor-beta in the regulation of T cell-independent resistance to Toxoplasma gondii. Eur J Immunol. 1995 Apr;25(4):994–1000. doi: 10.1002/eji.1830250420. [DOI] [PubMed] [Google Scholar]
  16. Jeannin P., Delneste Y., Seveso M., Life P., Bonnefoy J. Y. IL-12 synergizes with IL-2 and other stimuli in inducing IL-10 production by human T cells. J Immunol. 1996 May 1;156(9):3159–3165. [PubMed] [Google Scholar]
  17. Johnson P. C., Khardori N., Najjar A. F., Butt F., Mansell P. W., Sarosi G. A. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Aug;85(2):152–158. doi: 10.1016/s0002-9343(88)80334-6. [DOI] [PubMed] [Google Scholar]
  18. Lin S. H., Medoff G., Kobayashi G. S. Effects of amphotericin B on macrophages and their precursor cells. Antimicrob Agents Chemother. 1977 Jan;11(1):154–160. doi: 10.1128/aac.11.1.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Medoff G., Valeriote F., Lynch R. G., Schlessinger D., Kobayashi G. S. Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. Cancer Res. 1974 May;34(5):974–978. [PubMed] [Google Scholar]
  20. Morris S. C., Madden K. B., Adamovicz J. J., Gause W. C., Hubbard B. R., Gately M. K., Finkelman F. D. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol. 1994 Feb 1;152(3):1047–1056. [PubMed] [Google Scholar]
  21. Newman S. L., Gootee L. Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun. 1992 Nov;60(11):4593–4597. doi: 10.1128/iai.60.11.4593-4597.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nightingale S. D., Parks J. M., Pounders S. M., Burns D. K., Reynolds J., Hernandez J. A. Disseminated histoplasmosis in patients with AIDS. South Med J. 1990 Jun;83(6):624–630. doi: 10.1097/00007611-199006000-00007. [DOI] [PubMed] [Google Scholar]
  23. O'Garra A., Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol. 1994 Jun;6(3):458–466. doi: 10.1016/0952-7915(94)90128-7. [DOI] [PubMed] [Google Scholar]
  24. Ortaldo J. R., Mason A. T., O'Shea J. J., Smyth M. J., Falk L. A., Kennedy I. C., Longo D. L., Ruscetti F. W. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol. 1991 Jun 1;146(11):3791–3798. [PubMed] [Google Scholar]
  25. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 1994 Jan 28;76(2):241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  26. Schmitt E., Hoehn P., Germann T., Rüde E. Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells. Eur J Immunol. 1994 Feb;24(2):343–347. doi: 10.1002/eji.1830240211. [DOI] [PubMed] [Google Scholar]
  27. Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Rüde E., Germann T. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol. 1994 Apr;24(4):793–798. doi: 10.1002/eji.1830240403. [DOI] [PubMed] [Google Scholar]
  28. Seder R. A., Gazzinelli R., Sher A., Paul W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188–10192. doi: 10.1073/pnas.90.21.10188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shirley S. F., Little J. R. Immunopotentiating effects of amphotericin B. I. Enhanced contact sensitivity in mice. J Immunol. 1979 Dec;123(6):2878–2882. [PubMed] [Google Scholar]
  30. Starnes H. F., Jr, Pearce M. K., Tewari A., Yim J. H., Zou J. C., Abrams J. S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed] [Google Scholar]
  31. Sypek J. P., Chung C. L., Mayor S. E., Subramanyam J. M., Goldman S. J., Sieburth D. S., Wolf S. F., Schaub R. G. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993 Jun 1;177(6):1797–1802. doi: 10.1084/jem.177.6.1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Thomas M. Z., Medoff G., Kobayashi G. S. Changes in murine resistance to Listeria monocytogenes infection induced by amphotericin B. J Infect Dis. 1973 Apr;127(4):373–377. doi: 10.1093/infdis/127.4.373. [DOI] [PubMed] [Google Scholar]
  33. Tripp C. S., Wolf S. F., Unanue E. R. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3725–3729. doi: 10.1073/pnas.90.8.3725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wheat J., Hafner R., Wulfsohn M., Spencer P., Squires K., Powderly W., Wong B., Rinaldi M., Saag M., Hamill R. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1993 Apr 15;118(8):610–616. doi: 10.7326/0003-4819-118-8-199304150-00006. [DOI] [PubMed] [Google Scholar]
  35. Wheat L. J., Connolly-Stringfield P. A., Baker R. L., Curfman M. F., Eads M. E., Israel K. S., Norris S. A., Webb D. H., Zeckel M. L. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990 Nov;69(6):361–374. doi: 10.1097/00005792-199011000-00004. [DOI] [PubMed] [Google Scholar]
  36. Wolf J. E., Massof S. E. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun. 1990 May;58(5):1296–1300. doi: 10.1128/iai.58.5.1296-1300.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wolf S. F., Temple P. A., Kobayashi M., Young D., Dicig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewick R. M. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991 May 1;146(9):3074–3081. [PubMed] [Google Scholar]
  38. Wynn T. A., Cheever A. W., Jankovic D., Poindexter R. W., Caspar P., Lewis F. A., Sher A. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature. 1995 Aug 17;376(6541):594–596. doi: 10.1038/376594a0. [DOI] [PubMed] [Google Scholar]
  39. Wysocka M., Kubin M., Vieira L. Q., Ozmen L., Garotta G., Scott P., Trinchieri G. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol. 1995 Mar;25(3):672–676. doi: 10.1002/eji.1830250307. [DOI] [PubMed] [Google Scholar]
  40. Zhou P., Sieve M. C., Bennett J., Kwon-Chung K. J., Tewari R. P., Gazzinelli R. T., Sher A., Seder R. A. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol. 1995 Jul 15;155(2):785–795. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES